Panacea Global Announces Its Official Partnership With UICC

Panacea Global Announces Its Official Partnership With UICC 
TORONTO, ONTARIO -- (Marketwire) -- 01/21/13 -- Panacea Global, Inc.
("Panacea") (OTCBB:PANG) a biotechnology company focused on the
discovery, development and commercialization of diagnostic products
for the management of cancer, announced today that it has joined the
Union for International Cancer Control (UICC) in an international
partnership also known as its Champions Programme.  
UICC works in partnership with corporations and organizations through
its Champions programme to support priority programmes that benefit
the global cancer community and drive action on a global scale. Other
notable partners include Bayer, Roche, GSK, Sanofi and a number of
their member organizations. 
"We are privileged to be given the opportunity to join this
prestigious organization that is playing an important role in fight
against cancer", commented Dr. Moshiri, Panacea's President and CEO.
"This partnership will be valuable to Panacea's plans to further
promote its revolutionary cancer diagnostic technology within the
global medical community. 
Panacea Global's President & CEO, Dr. Moshiri has had the honour of
joining UICC's most recent global roundtable meeting held on January
16th, 2013 in Washington D.C. The roundtable event was co-hosted by
the UICC and the American Society of Clinical Oncology (ASCO) on the
topic of personalized medicine.  
About the Union for International Cancer Control (UICC) 
The Union for International Cancer Control (UICC) is a membership
organization that exists to help the global health community
accelerate the fight against cancer. Founded in 1933 and based in
Geneva, Switzerland, UICC's growing membership of over 760
organizations across 155 countries, features the world's major cancer
societies, ministries of health, research institutes and patient
groups. Together with its members, key partners, the World Health
Organization, World Economic Forum and others, UICC is tackling the
growing cancer crisis on a global scale. For more information, please
visit www.uicc.org. 
About Panacea Global 
Panacea Global is a biotechnology company focused on the development
and commercialization of diagnostic products for the management of
cancer. Panacea has developed an accurate, timely, cost effective and
non-invasive early cancer detection test to increase the quality of
life of cancer patients and ultimately saving lives. Panacea's test
is based on the detection of the human aspartyl (asparaginyl)
beta-hydroxylase (HAAH), a novel biomarker expressed in malignant
cancer cells in patients' blood samples. Panacea Global has the
exclusive worldwide (excluding the USA) rights to HAAH-based cancer
tests. More information about Panacea Global (OTCBB:PANG) is
available at www.panaceaglobalinc.com. 
Forward-looking statements 
Certain information contained in this document may include
"forward-looking information". Without limiting the foregoing, the
information and any forward-looking information may include
statements regarding projects, costs, objectives and future returns
of the Company or hypotheses underlying these items. In this
document, words such as "may", "would", "could", "will", "likely",
"believe", "expect", "anticipate", "intend", "plan", "estimate" and
similar words and the negative form thereof are used to identify
forward-looking statements. Forward-looking statements should not be
read as guarantees of future performance or results, and will not
necessarily be accurate indications of whether, or the times at or by
which, such future performance will be achieved. Forward-looking
statements and information are based on information available at the
time and/or the Company management's good-faith beliefs with respect
to future events and are subject to known or unknown risks,
uncertainties, assumptions and other unpredictable factors, many of
which are beyond the Company's control. The Company does not intend,
nor does it undertake, any obligation to update or revise any
forward-looking information or statements contained in this document
to reflect subsequent information, events or circumstances or
otherwise, except as required by applicable laws.
Contacts:
Panacea Global, Inc.
Dr. Saeid Babaei
+1 (905) 881-1049
ir@panaceaglobalinc.com
www.panaceaglobalinc.com